Grifols S.A. reports Q3 results; says on track to meet its 2026 guidance

• Grifols S.A. press release (GRFS): Q3 Revenue of €2.04B (+9.7% Y/Y).

  Adjusted EBITDA for the first nine months reached EUR 1,392 million, up 5.0% cc, with a margin of 24.8%. In the third quarter, adjusted EBITDA totaled EUR 538 million, with a margin of 26.4%

  ●

  The company’s net profit reached EUR 162 million in the third quarter, bringing year-to-date net profit through September to EUR 390 million, an increase of 28.4%

  ●

  Free cash flow pre-M&A pre-dividends improved by EUR 110 million year-over-year to EUR 298 million, including EUR 208 million in the third quarter

  ●

  The net leverage ratio declined to 3.98x, compared with 4.2x in the same period of 2025, while liquidity increased to EUR 2,140 million

  ●

  Grifols remains on track to meet its 2026 guidance

  ●

  Grifols Egypt is on track to collect approximately one million liters of plasma in 2026 Following the completion of the refinancing of its 2027 obligations, Grifols faces no significant maturities until the fourth quarter of 2028, further strengthening its financial flexibility.

Recommended For You

Create Your Free Account to Keep Reading

Get the confidence to navigate an uncertain market with free breaking news and stock alerts.